Mirvetuximab soravtansine

Mirvetuximab soravtansine

国际站：Mirvetuximab soravtansine

CAS：1453084-37-1

品牌：MedChemExpress (MCE)

存储条件：-80°C, protect from light

生物活性：Mirvetuximab soravtansine (IMGN853) 是一种抗体药物偶联物 (ADC)，由细胞毒性 maytansoid DM4 组成，共价连接到人源化单克隆抗体 M9346A。Mirvetuximab soravtansine 选择性结合叶酸受体1 (FOLR1)。Mirvetuximab soravtansine 具有抑制生长和增强 DNA 损伤的抗增殖作用。

体外：Mirvetuximab soravtansine (IMGN853; 8 nM; 6 h; IGROV-1 细胞) 与 Carboplatin (HY-17393) 的结合在体外促进协同生长抑制作用和细胞周期扰动[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内：Mirvetuximab soravtansine (IMGN853; 5 mg/kg; i.v.; SCID 雌性小鼠患者来源的异种移植模型) 增强 Carboplatin 的体内抗肿瘤活性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female severe combined immunodeficient (SCID) mice with patient-derived xenografts[1] Dosage: 5 mg/kg; 80 mg/kg (Carboplatin) Administration: Intravenous injection; two consecutive weekly doses Result: Suppressed tumor growth and combination therapy induced the greatest degree of tumor growth inhibition. Clinical Trial

参考文献：
[1]. Ponte JF, et, al. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. Neoplasia. 2016 Dec;18(12):775-784.